Slingshot members are tracking this event:

Baxalta Commences Phase 1 Clinical Trial of BAX 826, the Company’s Second Extended Half-Life Factor VIII Treatment for Hemophilia A

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Baxalta has dosed the first patient in its Phase 1, first-in-human clinical trial of BAX 826, a recombinant Factor VIII (rFVIII) treatment for hemophilia A that uses proprietary polysialic acid (PSA) technology to extend its circulating half-life. BAX 826 is under investigation as Baxalta’s second extended half-life treatment based on ADVATE [Antihemophilic Factor (Recombinant)], the world's most prescribed FVIII treatment.

BAX 826 is a next-generation rFVIII treatment based on the full length ADVATE. The compound is modified using proprietary polysialic acid (PSA) technology licensed from Xenetic Biosciences, Inc. (OTCQB: XBIO) to extend its circulating half-life. Baxalta has partnered with Xenetic to develop novel forms of polysialylated blood coagulation factors, including FVIII. Xenetic’s PolyXen™ technology utilizes the biopolymer PSA in order to extend the circulating half-life and potentially improve the pharmacokinetic profile of therapeutic proteins, peptides, and small molecules. Preclinical studies indicated BAX 826 offered an extended circulating half-life compared to standard rFVIII.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 04, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Bax 826, Half-life Factor Viii Treatment, Hemophilia A, Phase 1